Ninfa Candela to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Ninfa Candela has written about Inflammatory Bowel Diseases.
Connection Strength
0.479
-
Kaplan JL, Liu C, King EC, Bass JA, Patel AS, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti RB. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort. J Pediatr Gastroenterol Nutr. 2023 05 01; 76(5):566-575.
Score: 0.190
-
Ungaro RC, Chou B, Mo J, Ursos L, Twardowski R, Candela N, Colombel JF. Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA. J Crohns Colitis. 2022 Sep 08; 16(9):1405-1414.
Score: 0.184
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
Score: 0.053
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
Score: 0.053